Mets-blocker.

Beta-blockers are generating hype surrounding their ability to curb cancer progression, most recently fueled by this Norwegian cancer registry study revealing the 2% of patients on a non-selective beta blocker (e.g., propranolol) during an upfront radical prostatectomy for prostate cancer performed 2008-2015 had significantly lower risk of requiring salvage treatment. | Sivanesan, JAMA Netw Open 2022

Comments

Popular Posts